Regenerative medicine company Aziyo Biologics on June 29 launched OsteoGro V, a viable cell bone matrix to assist with bone repair.
Three things to know:
1. OsteoGro V features cancellous bone particles and demineralized cortical bone particles and fibers to improve product handling.
2. Aziyo Biologics has entered into several private-label distribution agreements, which is expected to boost adoption in the spine, orthopedic and dental markets.
3. Founded in 2015, Aziyo Biologics' products focus on improving outcomes in implantable device- related complications.